ATE510539T1 - Modifizierte prodrug-formen von ap - Google Patents
Modifizierte prodrug-formen von apInfo
- Publication number
- ATE510539T1 ATE510539T1 AT01979800T AT01979800T ATE510539T1 AT E510539 T1 ATE510539 T1 AT E510539T1 AT 01979800 T AT01979800 T AT 01979800T AT 01979800 T AT01979800 T AT 01979800T AT E510539 T1 ATE510539 T1 AT E510539T1
- Authority
- AT
- Austria
- Prior art keywords
- prodrug forms
- ocf3
- och3
- modified prodrug
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24052900P | 2000-10-13 | 2000-10-13 | |
PCT/US2001/032085 WO2002030424A1 (en) | 2000-10-13 | 2001-10-15 | Modified prodrug forms of ap/amp |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE510539T1 true ATE510539T1 (de) | 2011-06-15 |
Family
ID=22906907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01979800T ATE510539T1 (de) | 2000-10-13 | 2001-10-15 | Modifizierte prodrug-formen von ap |
Country Status (13)
Country | Link |
---|---|
US (1) | US6458816B1 (de) |
EP (1) | EP1335726B1 (de) |
JP (1) | JP4162994B2 (de) |
KR (1) | KR20030063360A (de) |
CN (1) | CN1224388C (de) |
AT (1) | ATE510539T1 (de) |
AU (2) | AU1172502A (de) |
BR (1) | BR0114598A (de) |
CA (1) | CA2423220C (de) |
HK (1) | HK1058005A1 (de) |
MX (1) | MXPA03003161A (de) |
RU (1) | RU2003113538A (de) |
WO (1) | WO2002030424A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002085358A2 (en) * | 2001-04-20 | 2002-10-31 | Vion Pharmaceuticals, Inc. | Antiviral agents and methods of treating viral infections |
US20070134660A1 (en) * | 2003-05-30 | 2007-06-14 | Rosetta Inpharmatics Llc | Methods for identifying modulators of kinesin activity |
US6855695B2 (en) | 2003-06-13 | 2005-02-15 | Vion Pharmaceuticals, Inc. | Water-soluble SHPs as novel alkylating agents |
US8969372B2 (en) | 2003-11-14 | 2015-03-03 | Aptose Boisciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
MXPA06006291A (es) * | 2003-12-08 | 2006-08-23 | Univ Arizona | Composiciones anti-cancer sinergisticas. |
CN101014353A (zh) | 2004-03-26 | 2007-08-08 | 维奥恩药品公司 | 包含CloretazineTM的治疗组合物 |
AU2005286833B2 (en) * | 2004-09-21 | 2012-02-16 | Nanoshift, Llc | Sulfonyl hydrazines as hypoxia-selective antineoplastic agents |
AU2006250809B2 (en) | 2005-05-25 | 2011-05-12 | Lorus Therapeutics Inc. | 2-indolyl imidazo(4,5-D)phenanthroline derivatives and their use in the treatment of cancer |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
CA2903866A1 (en) | 2013-03-20 | 2014-09-25 | Aptose Biosciences Inc. | 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer |
US20150104392A1 (en) | 2013-10-04 | 2015-04-16 | Aptose Biosciences Inc. | Compositions, biomarkers and their use in the treatment of cancer |
CA3081261A1 (en) | 2017-10-30 | 2019-05-09 | Aptose Biosciences Inc. | Aryl imidazoles for the treatment of cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5767134A (en) * | 1997-05-15 | 1998-06-16 | Vion Pharmaceuticals, Inc. | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP |
WO2002085358A2 (en) * | 2001-04-20 | 2002-10-31 | Vion Pharmaceuticals, Inc. | Antiviral agents and methods of treating viral infections |
-
2001
- 2001-10-15 RU RU2003113538/04A patent/RU2003113538A/ru not_active Application Discontinuation
- 2001-10-15 JP JP2002533865A patent/JP4162994B2/ja not_active Expired - Fee Related
- 2001-10-15 EP EP01979800A patent/EP1335726B1/de not_active Expired - Lifetime
- 2001-10-15 BR BR0114598-3A patent/BR0114598A/pt not_active IP Right Cessation
- 2001-10-15 US US09/977,659 patent/US6458816B1/en not_active Expired - Lifetime
- 2001-10-15 WO PCT/US2001/032085 patent/WO2002030424A1/en active IP Right Grant
- 2001-10-15 CN CNB018169236A patent/CN1224388C/zh not_active Expired - Lifetime
- 2001-10-15 AU AU1172502A patent/AU1172502A/xx active Pending
- 2001-10-15 AT AT01979800T patent/ATE510539T1/de not_active IP Right Cessation
- 2001-10-15 CA CA2423220A patent/CA2423220C/en not_active Expired - Lifetime
- 2001-10-15 MX MXPA03003161A patent/MXPA03003161A/es unknown
- 2001-10-15 AU AU2002211725A patent/AU2002211725B2/en not_active Expired
- 2001-10-15 KR KR10-2003-7005178A patent/KR20030063360A/ko not_active Application Discontinuation
-
2004
- 2004-02-10 HK HK04100869A patent/HK1058005A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1224388C (zh) | 2005-10-26 |
EP1335726B1 (de) | 2011-05-25 |
EP1335726A1 (de) | 2003-08-20 |
CN1468102A (zh) | 2004-01-14 |
CA2423220C (en) | 2012-01-03 |
KR20030063360A (ko) | 2003-07-28 |
BR0114598A (pt) | 2003-07-01 |
AU1172502A (en) | 2002-04-22 |
US6458816B1 (en) | 2002-10-01 |
EP1335726A4 (de) | 2009-03-25 |
US20020119955A1 (en) | 2002-08-29 |
JP4162994B2 (ja) | 2008-10-08 |
CA2423220A1 (en) | 2002-04-18 |
RU2003113538A (ru) | 2004-11-10 |
AU2002211725B2 (en) | 2005-06-30 |
JP2004510818A (ja) | 2004-04-08 |
MXPA03003161A (es) | 2004-05-05 |
WO2002030424A1 (en) | 2002-04-18 |
HK1058005A1 (en) | 2004-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE510539T1 (de) | Modifizierte prodrug-formen von ap | |
NO20032625D0 (no) | Indazolylsubstituerte pyrrolinforbindelser som kineaseinhibitorer | |
DE60236600D1 (de) | Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung | |
CY1107199T1 (el) | Καρβαμικες ενωσεις για χρηση στη προληψη ή τη θεραπευτικη αντιμετωπιση της διπολικης διαταραχης | |
DK1485359T3 (da) | Natriumkanalblokkere | |
TW200626559A (en) | Anilino-pyrimidine analogs | |
TNSN06405A1 (en) | Quinazolinone derivatives useful as vanilloid antagonistes | |
CY1105330T1 (el) | Καρβαμιδικα παραγωγα για χρηση στην προληψη ή την αγωγη της διπολικης διαταραχης | |
DE69918422D1 (de) | Phthalazinone pde iii/iv hemmer | |
BRPI0410870A (pt) | compostos trieterocìclicos, composições, e métodos para tratar cáncer ou doenças virais | |
CY1106924T1 (el) | Ενωσεις καρβαμικου για χρηση οσον αφορα την προληψη ή την αγωγη των διαταραχων κινησης | |
CY1107468T1 (el) | Καρβαμιδικες ενωσεις για χρηση στην προληψη ή την αγωγη διαταραχων του αγχους | |
CY1106753T1 (el) | Καρβαμιδικαι ενωσεις δια χρησιν εις προληψιν ή νοσηλειαν νευροεκφυλιστικων διαταραχων | |
CY1111349T1 (el) | Καρβαμιδικες ενωσεις προς χρηση στη θεραπεια του πονου | |
UY27852A1 (es) | Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
NO20050871L (no) | 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer | |
MX2023002224A (es) | Compuestos heterociclicos. | |
MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
MX2023009045A (es) | Derivados novedosos de pirimidin-2-il sulfonamida. | |
CR20230529A (es) | Inhibidores de nlrp3 | |
NO20022977D0 (no) | Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter | |
ATE276259T1 (de) | Dihydroporphyrinderivate und ihre verwendung | |
CY1109429T1 (el) | Καρβαμιδικες ενωσεις για χρηση στην προληψη ή τη θεραπεια του πονου λογω νευροπαθειας | |
DK1651596T3 (da) | Hidtil ukendte derivater af 4,4'-dithiobis-(3-aminobutan-1-sulfonater) og sammensætninger, der omfatter samme | |
UY26866A1 (es) | Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenilpirido (2,3-d) pirimidin-7-onas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |